3-FMC - Substance Search

Summary TheDrug.Wiki TripSit

Extremely caustic to nasal mucosa; users report intense burn and chronic rhinitis after repeated insufflation. Strong vasoconstriction requires monitoring extremity temperature. Severe hyponatremia reported in prolonged binges; maintain balanced electrolyte intake.

Dose Information TheDrug.Wiki TripSit

ROA	Light	Common	Strong	Heavy
Oral	25-50mg	50-100mg	100-150mg	150mg+

Light Common Strong Heavy

Onset, Duration & After-effects TheDrug.Wiki TripSit

ROA	Onset	Comeup	Peak	Offset	After Effects	Total
Oral	10-30 min	15-30 min	60-90 min	1-2 hrs	2-6 hrs	2.4-4.5 hrs
Insufflated	2-10 min	5-15 min	60-90 min	1-2 hrs	2-6 hrs	2.1-3.9 hrs
Rectal	5-20 min	10-20 min	60-90 min	1-2 hrs	2-6 hrs	2.2-4.2 hrs

Effect Profile

Scores (1–10) curated from multiple sources:

Effect keyword matching from PsychonautWiki catalog
Weighted by importance: core (×3), major (×2), minor (×1)

Full methodology

Empathogen 4.9

Moderate+ 5/10

Moderate stimulation with mild euphoria, sensory enhancement, and empathy

Empathy / Social Openness ×3

4

enhanced sociability increased sociability

Euphoria / Mood Elevation ×2

5

euphoria mood lift

Stimulation ×1

7

stimulation increased energy teeth grinding

Sensory Enhancement ×1

5

tactile enhancement increased libido

Stimulant 4.9

Moderate+ 5/10

Strong anxiety/jitters with moderate euphoria, mild stimulation and focus

Stimulation / Energy ×3

5

stimulation increased energy

Euphoria / Mood Lift ×2

7

euphoria mood lift motivation enhancement

Focus / Productivity ×2

5

focus enhancement motivation enhancement

⚠ Anxiety / Jitters ×1

10

anxiety paranoia teeth grinding bruxism sweating

Based on reports from:

Erowid Experience Reports PsychonautWiki 3-FMC

Tolerance

Build-up develops rapidly, often within a single session; compulsive redosing common

Reset a few days for acute tolerance

Tolerance Decay

Full tolerance 1d Half tolerance 7d Baseline ~30d

Cathinone stimulants often exhibit rapid within‑session tolerance with partial recovery over 1–2 weeks and nearer‑baseline by 4–6 weeks; values are heuristic from community reports and analogous agents, not formal PK/PD data.